Navigation Links
Revised: Othera Pharmaceuticals Appoints Dr. Frederick R. Rickles Chief Scientific Officer
Date:10/2/2007

he CEO and Executive Director of the Federation of American Societies for Experimental Biology (FASEB), a coalition of 21 leading life science research organizations. He also served as a scientific advisor for multiple leading pharmaceutical and private sector companies and such as Pfizer and Caremark, respectively.

Rickles is a graduate of the University of Illinois College of Medicine and trained in internal medicine and hematology at the University of Rochester/Strong Memorial Hospital. He will continue to serve as a Professor of Medicine in the Division of Hematology-Oncology, Department of Medicine at GWU. He will also maintain his position as a teaching attending physician at the GWU Hospital in Washington, DC. Rickles will also continue to serve as member of multiple editorial boards, medical association committees, and scientific advisory boards.

About Othera Pharmaceuticals

Founded in 2002, Othera Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing novel, patient-administered products for ophthalmology, oncology, and inflammatory diseases.

Othera's most advanced product is currently in Phase 2 clinical trials for the treatment of major age-related macular degeneration (AMD). OT-551 is a novel small molecule that inhibits oxidative stress and disease-induced inflammatory responses that contribute to loss of vision in AMD patients. "OT-551 is topically dosed in an eye drop and has the unique ability to penetrate cell membranes and reach both the front and the back of the eye," said David S. Joseph, chairman and CEO of Othera Pharmaceuticals. "We are very encouraged by preclinical research results demonstrating that OT-551 may be the first drug treatment for both the dry and wet form of age-related macular degeneration (AMD). Two Phase 2 trials of OT-551 in AMD patients are currently underway with initial results expected in 2008."

In addition to its lead compound, OT-551, Othera is also developing OT
'/>"/>

SOURCE Othera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. TomoTherapy opens technical training center
3. TomoTherapy raises $223 million in IPO
4. TomoTherapy revises IPO money target
5. Hospital named for Madame Curie installs TomoTherapy system
6. TomoTherapy files registration statement for IPO
7. TomoTherapy to sell medical devices in India
8. TomoTherapy sees sustained market advantage
9. TomoTherapys 100th radiology system reaches public sector
10. TomoTherapy extends reach to Germany
11. Cash-rich TomoTherapy has no plans for IPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014 Gene synthesis and ... has entered into a technology access and services ... apply DNA2.0’s proprietary protein engineering technology, known as ... “We are extremely excited that the global leader ... This proprietary bioengineering technology has now been validated ...
(Date:12/17/2014)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), ... commercialization of innovative therapeutics addressing cancer and other unmet ... commercial focus on China , today ... meeting with the U.S. Food and Drug Administration (FDA) ... 2015.  During this meeting the Company will seek guidance ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)... , Dec. 15, 2014  Ascendis Pharma ... TransCon technology to address significant unmet medical needs, ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  This interim analysis consists of ... total enrollment in the study, completing all six ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4
... , , , ... now offers new larger pack sizes,of PCR-Grade Nucleotides. These larger pack sizes,combine the best available quality ... , , Single dNTPs , ... Single dNTPs are now available in 500-mol pack sizes.,The Deoxynucleoside Triphosphate Set, containing all four ...
... , , ... , , , With the introduction of ... the robust amplification of fragments up to,3 kb, providing the highest possible fidelity ... , , , Pwo Master is a ...
... , ... , , , ... for the detection and quantitation,of mRNA species. The assay was made ... T3). These enzymes possess several properties that,make them well suited for ...
Cached Biology Technology:PCR-Grade Nucleotides,Larger Pack Sizes Now Available 2Pwo Master*:,Simplify Setup of Your Proofreading PCRs 2Pwo Master*:,Simplify Setup of Your Proofreading PCRs 3RNase Protection Assay (RPA),Using DIG-Labeled RNA Probes 2
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)... , Nov. 17, 2014   ... EMC collaborate to develop The Partners Data Lake, ... The Partners Data Lake will allow researcher and ... diagnostics, treatment and the lives of patients ... and clinical activities across the Partners system, breaking ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock Inc. ... solutions, and MorphoTrust USA (Safran), a ... today announced a strategic partnership to offer comprehensive ... vehicle administration (MVA), airport screening and financial services ... solutions, MorphoTrust serves consumers through a nationwide network ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... led by Simon Fraser University,s Gerontology Research Centre (GRC) ... (SEI) is tracking attitudes about the environment among those ... of organizations, will provide a snapshot of current attitudes ... change. The survey aims to identify difficulties ...
... of meanings. Fluid flow in the human body is ... and pathogens that travel through the air. In fact, ... plethora of biological activities. Even the motions of a basketball ... a dynamical system. For the past eight years, ...
... have already been introduced into the wild on a ... release of genetically modified animals is still at a ... Max Planck Institute for Evolutionary Biology in Pln, Germany ... of genetically modified insects in Malaysia, USA, and Cayman ...
Cached Biology News:Survey tracks '55+' attitudes about the environment 2Shane Ross garners CAREER Award to advance understanding of fluid flows from blood inside the body to oil spills in bodies of water 2Shane Ross garners CAREER Award to advance understanding of fluid flows from blood inside the body to oil spills in bodies of water 3Transgene insects: Scientists call for more open data 2Transgene insects: Scientists call for more open data 3Transgene insects: Scientists call for more open data 4
Rubeola (Measles) Antigen Preservative: No Preservatives...
... at least 20 structurally and functionally related ... superfamily. BMPs were originally identified as protein ... are also involved in embryogenesis and morphogenesis ... the growth, differentiation, chemotaxis and apoptosis of ...
One-step, microplate or cuvet, colorimetric 530nm, detection limit 0.16mg/dL in serum or plasma. Procedure: 10 min....
One-step, microplate or cuvet, colorimetric, detection range 0.01 g/dL to 5 g/dL. Procedure: 5 min....
Biology Products: